Lodenafil

CAS No. 139755-85-4

Lodenafil ( Hydroxyhomosildenafil )

Catalog No. M20715 CAS No. 139755-85-4

Lodenafil is a potent PDE5 inhibitor with treatment of erectile dysfunction (ED).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 60 In Stock
5MG 87 In Stock
10MG 147 In Stock
25MG 293 In Stock
50MG 509 In Stock
100MG 711 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Lodenafil
  • Note
    Research use only not for human use.
  • Brief Description
    Lodenafil is a potent PDE5 inhibitor with treatment of erectile dysfunction (ED).
  • Description
    Lodenafil is a potent PDE5 inhibitor with treatment of erectile dysfunction (ED).
  • Synonyms
    Hydroxyhomosildenafil
  • Pathway
    Angiogenesis
  • Target
    PDE
  • Recptor
    PDE
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    139755-85-4
  • Formula Weight
    504.6
  • Molecular Formula
    C23H32N6O5S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:250 mg/mL (495.44 mM)
  • SMILES
    CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CCO)CC1
  • Chemical Name
    5-(2-Ethoxy-5-((4-(2-hydroxyethyl)-1-piperazinyl)sulfonyl)phenyl)-16-dihydro-1-Methyl-3-propyl-7H-pyrazolo(43-d)pyriMidin-7-one

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Polonio I B Acencio M M P Pazetti Rogério et al. Lodenafil treatment in the monocrotaline model of pulmonary hypertension in rats[J]. Jornal Brasileiro de Pneumologia 2014 40(4):421-424.
molnova catalog
related products
  • Triflusal

    Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981.

  • Luteolin

    Luteolin is a falconoid compound, which exhibits anticancer properties.

  • PQ-10

    PQ-10 is a PDE-10 inhibitor. PQ-10 induces brain glucose metabolism patterns, which may be a potential translational biomarker.